Allergan, Inc. (AGN), Regeneron Pharmaceuticals Inc (REGN), And What You Should Know

Now what: And this is precisely why I wanted Eylea as my lead drug candidate in my fantasy biotech draft! There really isn’t a drug out there that’s set to challenge Eylea’s dominance in wet-AMD, and Eylea trumps Novartis and Roche’s Lucentis on price, albeit marginally. For Allergan, Inc. (NYSE:AGN), it’s been a disappointing day. More so, I’m growing concerned with two recent defeats to its development pipeline. While I do expect an eventual approval for Levadex, investors had been counting on DARPin to add to Allergan’s impressive product portfolio. With DARPin now on hold, Allergan has lost a lot of its luster.

Craving more input? Start by adding Allergan, Inc. (NYSE:AGN) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to your free and personalized Watchlist so you can keep up on the latest news with these companies.

The article Why Allergan’s Pain Is Regeneron’s Gain originally appeared on Fool.com.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.